Search

Your search keyword '"Bao, Yuqian"' showing total 560 results
Start Over Author "Bao, Yuqian" Search Limiters Peer Reviewed
560 results on '"Bao, Yuqian"'

1. Effectiveness of Smartphone App–Based Interactive Management on Glycemic Control in Chinese Patients With Poorly Controlled Diabetes: Randomized Controlled Trial

Author

Zhang, Lei, He, Xingxing, Shen, Yun, Yu, Haoyong, Pan, Jiemin, Zhu, Wei, Zhou, Jian, and Bao, Yuqian

Subjects
Computer applications to medicine. Medical informatics, R858-859.7, Public aspects of medicine, RA1-1270
Abstract

BackgroundIn recent years, the rapid development of mobile medical technology has provided multiple ways for the long-term management of chronic diseases, especially diabetes. As a new type of management model, smartphone apps are global, convenient, cheap, and interactive. Although apps were proved to be more effective at glycemic control, compared with traditional computer- and Web-based telemedicine technologies, how to gain a further and sustained improvement is still being explored. ObjectiveThe objective of this study was to investigate the effectiveness of an app-based interactive management model by a professional health care team on glycemic control in Chinese patients with poorly controlled diabetes. MethodsThis study was a 6-month long, single-center, prospective randomized controlled trial. A total of 276 type 1 or type 2 diabetes patients were enrolled and randomized to the control group (group A), app self-management group (group B), and app interactive management group (group C) in a 1:1:1 ratio. The primary outcome was the change in glycated hemoglobin (HbA1c) level. Missing data were handled by multiple imputation. ResultsAt months 3 and 6, all 3 groups showed significant decreases in HbA1c levels (all P.05). Multivariate line regression analyses also showed that the app interactive management group was associated with the larger reduction of HbA1c compared with groups A and B at both months 3 and 6 (all P>.05). In addition, the app interactive management group had better control of triglyceride and high-density lipoprotein cholesterol levels at both months 3 and 6 compared with baseline (both P

Published
2019
Full Text
View/download PDF

5. Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota

Author

Li, Huating, Zhang, Lei, Li, Jun, Wu, Qian, Qian, Lingling, He, Junsheng, Ni, Yueqiong, Kovatcheva-Datchary, Petia, Yuan, Rui, Liu, Shuangbo, Shen, Li, Zhang, Mingliang, Sheng, Bin, Li, Ping, Kang, Kang, Wu, Liang, Fang, Qichen, Long, Xiaoxue, Wang, Xiaolin, Li, Yanli, Ye, Yaorui, Ye, Jianping, Bao, Yuqian, Zhao, Yueliang, Xu, Guowang, Liu, Xinyu, Panagiotou, Gianni, Xu, Aimin, and Jia, Weiping

Published
2024
Full Text
View/download PDF

12. Large language models for diabetes care: Potentials and prospects

Author

Sheng, Bin, Guan, Zhouyu, Lim, Lee-Ling, Jiang, Zehua, Mathioudakis, Nestoras, Li, Jiajia, Liu, Ruhan, Bao, Yuqian, Bee, Yong Mong, Wang, Ya-Xing, Zheng, Yingfeng, Tan, Gavin Siew Wei, Ji, Hongwei, Car, Josip, Wang, Haibo, Klonoff, David C., Li, Huating, Tham, Yih-Chung, Wong, Tien Yin, and Jia, Weiping

Published
2024
Full Text
View/download PDF

29. Low-dose metformin targets the lysosomal AMPK pathway through PEN2

Author

Ma, Teng, Tian, Xiao, Zhang, Baoding, Li, Mengqi, Wang, Yu, Yang, Chunyan, Wu, Jianfeng, Wei, Xiaoyan, Qu, Qi, Yu, Yaxin, Long, Shating, Feng, Jin-Wei, Li, Chun, Zhang, Cixiong, Xie, Changchuan, Wu, Yaying, Xu, Zheni, Chen, Junjie, Yu, Yong, Huang, Xi, He, Ying, Yao, Luming, Zhang, Lei, Zhu, Mingxia, Wang, Wen, Wang, Zhi-Chao, Zhang, Mingliang, Bao, Yuqian, Jia, Weiping, Lin, Shu-Yong, Ye, Zhiyun, Piao, Hai-Long, Deng, Xianming, Zhang, Chen-Song, and Lin, Sheng-Cai

Published
2022
Full Text
View/download PDF

38. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism

Author

Zheng, Xiaojiao, Chen, Tianlu, Jiang, Runqiu, Zhao, Aihua, Wu, Qing, Kuang, Junliang, Sun, Dongnan, Ren, Zhenxing, Li, Mengci, Zhao, Mingliang, Wang, Shouli, Bao, Yuqian, Li, Huating, Hu, Cheng, Dong, Bing, Li, Defa, Wu, Jiayu, Xia, Jialin, Wang, Xuemei, Lan, Ke, Rajani, Cynthia, Xie, Guoxiang, Lu, Aiping, Jia, Weiping, Jiang, Changtao, and Jia, Wei

Published
2021
Full Text
View/download PDF

42. Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo.

Author

Bao, Yuqian, Han, Lin, Du, Liying, and Ji, Linong

Subjects
GLYCEMIC control, DIASTOLIC blood pressure, GLYCOSYLATED hemoglobin, TYPE 2 diabetes, BLOOD sugar
Abstract

Objective: The study objective was to characterize subgroups of Asia‐Pacific patients with type 2 diabetes who achieved different glycated hemoglobin (HbA1c) targets on tirzepatide treatment. Methods: This was a post hoc analysis of the SURPASS AP‐Combo study. Baseline characteristics, changes in metabolic markers, and safety were compared between tirzepatide‐treated patients achieving HbA1c <7.0% (<53 mmol/mol) and those achieving ≥7.0% (≥53 mmol/mol) at week 40. Among patients achieving HbA1c <7.0% (<53 mmol/mol), further comparisons were conducted among subgroups achieving HbA1c <5.7% (<39 mmol/mol), 5.7% to 6.5% (39 to 48 mmol/mol), and >6.5% to <7.0% (>48 to <53 mmol/mol). Results: Five hundred ninety‐eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]). Patients achieving HbA1c <7.0% (<53 mmol/mol) versus ≥7.0% (≥53 mmol/mol) were slightly younger with a shorter disease duration and lower HbA1c at baseline, and they had greater improvements in HbA1c, fasting serum glucose, body weight, BMI, waist circumference, waist‐height ratio, diastolic blood pressure, lipids, and self‐monitored blood glucose at week 40. Patients achieving HbA1c <5.7% (<39 mmol/mol) versus those achieving 5.7% to 6.5% (39 to 48 mmol/mol) and those achieving >6.5% to <7.0% (>48 to <53 mmol/mol) were much younger, had much lower HbA1c, and had further improvements in metabolic markers. Tirzepatide treatment was well tolerated irrespective of the HbA1c level achieved, with a low incidence of hypoglycemic events. Conclusions: These findings may help to inform clinical decisions in Asia‐Pacific patients with type 2 diabetes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Associations of change in body fat percentage with baseline body composition and diabetes remission after bariatric surgery.

Author

Li, Shaobo, Zhang, Pin, Di, Jianzhong, Han, Xiaodong, Tu, Yinfang, Yang, Di, Xu, Rongrong, Xiao, Yunfeng, Zhou, Jian, Bao, Yuqian, Yin, Jun, Yu, Haoyong, Jia, Weiping, and Han, Junfeng

Subjects
GASTRIC bypass, BARIATRIC surgery, BODY composition, DISEASE remission, FAT, SLEEVE gastrectomy
Abstract

Objective: The objective of this study was to determine the role of body fat percentage (BFP) changes in diabetes remission (DR) and the association between baseline body composition and its changes after bariatric surgery. Methods: We analyzed 203 patients with type 2 diabetes who underwent Roux‐en‐Y gastric bypass. Body composition was measured using a gold‐standard‐derived predictive equation and magnetic resonance imaging. Body composition changes were calculated as 100 × (baseline value – follow‐up value)/baseline value. We verified the results in a laparoscopic sleeve gastrectomy cohort with 311 patients. Results: Compared with non‐remission patients in the Roux‐en‐Y gastric bypass cohort, those who achieved DR showed a higher baseline fat‐free mass index (FFMI) and experienced the most significant changes in BFP (p < 0.001). In comparative analyses, BFP changes were significantly better than BMI changes in identifying short‐ and long‐term DR. Linear regression analysis identified FFMI as the most significant baseline variable correlated with BFP changes (p < 0.001). Baseline BMI was positively correlated with changes in BFP but negatively correlated with changes in FFMI. These findings were replicated in the laparoscopic sleeve gastrectomy cohort. Conclusions: BFP changes determine DR after bariatric surgery, and baseline FFMI is crucial for BFP changes. A low initial BMI is associated with a smaller BFP reduction and greater FFMI loss after bariatric surgery. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Adipocyte-Specific Hnrnpa1 Knockout Aggravates Obesity-Induced Metabolic Dysfunction via Upregulation of CCL2.

Author

Li, Xiaoya, Su, Yingying, Xu, Yiting, Hu, Tingting, Lu, Xuhong, Sun, Jingjing, Li, Wenfei, Zhou, Jian, Ma, Xiaojing, Yang, Ying, and Bao, Yuqian

Subjects
METABOLIC disorders, WHITE adipose tissue, ADIPOSE tissues, WEIGHT loss, LIVER histology, INSULIN sensitivity, GASTRIC bypass
Abstract

Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) is involved in lipid and glucose metabolism via mRNA processing. However, whether and how HNRNPA1 alters adipocyte function in obesity remain obscure. Here, we found that the obese state downregulated HNRNPA1 expression in white adipose tissue (WAT). The depletion of adipocyte HNRNPA1 promoted markedly increased macrophage infiltration and expression of proinflammatory and fibrosis genes in WAT of obese mice, eventually leading to exacerbated insulin sensitivity, glucose tolerance, and hepatic steatosis. Mechanistically, HNRNPA1 interacted with Ccl2 and regulated its mRNA stability. Intraperitoneal injection of CCL2-CCR2 signaling antagonist improved adipose tissue inflammation and systemic glucose homeostasis. Furthermore, HNRNPA1 expression in human WAT was negatively correlated with BMI, fat percentage, and subcutaneous fat area. Among individuals with 1-year metabolic surgery follow-up, HNRNPA1 expression was positively related to percentage of total weight loss. These findings identify adipocyte HNRNPA1 as a link between adipose tissue inflammation and systemic metabolic homeostasis, which might be a promising therapeutic target for obesity-related disorders. Article Highlights: Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) is decreased during obesity, but the specific role in adipose tissue remains unclear. Adipocyte-specific depletion of Hnrnpa1 accelerates adipose tissue inflammation and systemic metabolic disorders via enhancing mRNA stability of chemokine CCL2. CCL2 receptor antagonist rescues metabolic dysfunction elicited by Hnrnpa1 depletion. HNRNPA1 expression in human adipose tissue is closely related to BMI, fat percentage, and subcutaneous fat area and is positively associated with percentage of total weight loss 1 year after bariatric surgery. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results